Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
- PMID: 33569399
- PMCID: PMC7867951
- DOI: 10.21037/atm-20-7009
Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-20-7009). Dr. FD reports grants from Pfizer, from Ipsen, from MSD, outside the submitted work.
Figures

Comment on
-
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.J Clin Oncol. 2020 Jan 1;38(1):63-70. doi: 10.1200/JCO.19.01882. Epub 2019 Nov 13. J Clin Oncol. 2020. PMID: 31721643 Free PMC article. Clinical Trial.
-
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial.Eur Urol. 2021 May;79(5):659-662. doi: 10.1016/j.eururo.2020.06.021. Epub 2020 Jul 9. Eur Urol. 2021. PMID: 32654802 Free PMC article.
-
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.Clin Cancer Res. 2021 Jan 1;27(1):78-86. doi: 10.1158/1078-0432.CCR-20-2063. Epub 2020 Sep 1. Clin Cancer Res. 2021. PMID: 32873572 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources